open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-20
Get Citation

Diagnosis and treatment of patients with NSCLC EGFR Mut+

Ewa Skrzypczyńska

open access

Vol 10, Supp. G (2014)
suplement
Published online: 2015-03-20

Abstract

Using tyrosine kinase inhibitors in the second line of treatment in patients with adenocarcinoma and EGFR activated mutation may slightly prolong the survival time. In patients with adenocarcinoma, with a positive mutation in the EGFR gene and progression after treatment of chemioterapy platinum-based — the drug of choice is erlotinib at a daily dose 150 mg. The case study present a few months survival without progression patient with diagnosis NSCLC EGFR Mut+ treated with erlotinib in the second line.

Abstract

Using tyrosine kinase inhibitors in the second line of treatment in patients with adenocarcinoma and EGFR activated mutation may slightly prolong the survival time. In patients with adenocarcinoma, with a positive mutation in the EGFR gene and progression after treatment of chemioterapy platinum-based — the drug of choice is erlotinib at a daily dose 150 mg. The case study present a few months survival without progression patient with diagnosis NSCLC EGFR Mut+ treated with erlotinib in the second line.

Get Citation

Keywords

lung cancer, erlotinib, EGFR mutation

About this article
Title

Diagnosis and treatment of patients with NSCLC EGFR Mut+

Journal

Oncology in Clinical Practice

Issue

Vol 10, Supp. G (2014)

Pages

29-35

Published online

2015-03-20

Keywords

lung cancer
erlotinib
EGFR mutation

Authors

Ewa Skrzypczyńska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl